Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. We target the biotechnology industry, with an exclusive focus on therapeutics.
Founded in 2008, Ysios Capital has € 346M in assets under management through its three funds: Ysios BioFund I (€65 M), Ysios BioFund II Innvierte (€ 126M) and Ysios BioFund III (€ 155M), open to new investors.
Our team includes experienced professionals with extensive expertise in investing and building healthcare and biotechnology companies. Ysios Capital has access to a broad global network within academia, finance and industry. We take an active role in the development of our portfolio companies as a lead investor or as an active syndicate partner.
Ysios Capital is registered at Spanish Securities and Exchange Commission (CNMV) with offices in San Sebastián and Barcelona.
Our partner ED pharmacy site www.buylevitra1.com offers information about Levitra and other ED drugs
Ysios Capital is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive ”investments in the European Union and to ensure increased access to financing”.